Samfara Acquires Chr. Olesen Synthesis

Alfasigma to Acquire Nordic Group B.V. (Nordic Pharma)

August 11, 2026

Pharmaceuticals

Alfasigma S.p.A. has entered into a share purchase agreement with SEVER Life Sciences B.V. to acquire 100% of the shares of Nordic Group B.V. and its subsidiaries (Nordic Pharma). The deal will expand Alfasigma’s specialty rheumatology offering, including Nordic Pharma’s rheumatoid arthritis Nordimet (methotrexate) franchise, while also strengthening its commercial footprint in Europe, Canada, and Japan.

HAS Healthcare Advanced Synthesis Acquires Cerbios-Pharma to Form Leading CDMO Group

March 31, 2025

Healthcare Services

HAS Healthcare Advanced Synthesis SA (HAS) announced the planned acquisition of Cerbios-Pharma SA (Cerbios) to create a leading international CDMO group in Switzerland’s Ticino region. The combination brings complementary expertise in production, chemistry and biology, enabling expanded development and manufacturing services (including ADC-related capabilities), supported by 65 Equity Partners.

MidEuropa Acquires Controlling Stake in FAMAR

October 17, 2024

Pharmaceuticals

MidEuropa has acquired a controlling stake in FAMAR, a European contract development and manufacturing organisation (CDMO), from ECM Partners and Metric Capital Partners, with current shareholders and management reinvesting alongside MidEuropa. FAMAR employs around 1,900 people across six manufacturing sites and two R&D centres in southern Europe and will use MidEuropa's backing to support further growth and capability expansion in pharmaceutical manufacturing and R&D.

Formosa Laboratories Acquires SynChem to Expand North American CDMO Footprint

June 3, 2024

Pharmaceuticals

Formosa Laboratories, Inc., a Taiwan-based API supplier and CDMO, has completed its acquisition of SynChem, Inc., a contract research laboratory in suburban Chicago. SynChem will operate as SynChem-Formosa with Dr. W. Paul Mar remaining as CEO as the combined operations expand Formosa's US CDMO capabilities for small-molecule APIs and ADC-related chemistries.

Pharmacosmos A/S Acquires AbFero Pharmaceuticals, Inc.

November 11, 2021

Pharmaceuticals

Pharmacosmos A/S (Pharmacosmos Group) has agreed to acquire all assets of Boston-based clinical-stage AbFero Pharmaceuticals, Inc. under a share purchase agreement for up to $225 million including upfront, milestone, and royalty components. The acquisition adds AbFero’s SP-420 iron chelation program to Pharmacosmos’ iron-metabolism-focused R&D and commercial capabilities to accelerate development and commercialization for transfusional iron overload and related indications.

Thomas H. Lee Partners and Frazier Healthcare Partners Acquire Adare Pharmaceuticals

September 22, 2020

Pharmaceuticals

Thomas H. Lee Partners and Frazier Healthcare Partners have acquired Adare Pharmaceuticals (to be rebranded Adare Pharma Solutions) from TPG Capital. The deal includes Adare’s CDMO, pharmaceutical technology and microbiome businesses while TPG retained rights to an EoE product spun into a separate entity; terms were not disclosed.